Drug Trial Radar · NCT07105124
Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 18, 2022
Primary completion
Feb 15, 2023
Study completion Feb 15, 2023
Sponsor
- Lead sponsor
- Otsuka Beijing Research InstituteOtsuka
- Sponsor type
- Industry
- Collaborators
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects
Conditions
- Healthy Subjects (HS)
Interventions
SibeprenlimabDrug
Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sibeprenlimab serum concentrationsTime frame: Day 1 (predose, 4 hours postdose, and 8 hours postdose) and on Day 2 (24 hours postdose). All subjects will also have blood samples collected for PK analysis on Days 3, 5, 7, 9, 14 (Week 2), 28 (Week 4), 42 (Week 6), 56 (Week 8), 70 (Week 10), and 84
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.